Posted by Michael Wonder on 13 Apr 2022
Amneal achieves second U.S. biosimilars approval with Alymsys (bevacizumab-maly)
13 April 2022 - Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022.
Amneal Pharmaceuticals today announced that the U.S. FDA has approved the company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin.
